Dr. Daryl Dean Sandoval Martinez, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2299 Bacon St Ste 2, Concord, CA 94520 Phone: 925-676-2942 Fax: 925-676-7108 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.
Rising rates of opioid prescriptions have been linked to the opioid epidemic, and a significant number of opioid deaths have been linked to prescriptions written by surgeons.
A new study published as "Editor's Choice" in The Journal of Infectious Diseases found that expansion of HIV treatment eligibility to include those under age 15 led to large and significant increases in initiation of antiretroviral therapy within 30 days of enrollment in care among 10- to 14-year-olds living with HIV.
› Verified 3 days ago